tbuckley/cabot-search huggingface dataset:
Microanatomy of the Human Atherosclerotic Plaque by Single-Cell Transcriptomics
Authors: Marie A.C. Depuydt, Koen H.M. Prange, Lotte Slenders, Tiit Örd, Danny Elbersen, Arjan Boltjes, Saskia C.A. de Jager, Folkert W. Asselbergs, Gert J. de Borst, Einari Aavik, Tapio Lönnberg, Esther Lutgens, Christopher K. Glass, Hester M. den Ruijter, Minna U. Kaikkonen, Ilze Bot, Bram Slütter, Sander W. van der Laan, Seppo Yla-Herttuala, Michal Mokry, Johan Kuiper, Menno P.J. de Winther, Gerard Pasterkamp
Journal: Circulation Research (2020)

Atherosclerotic lesions are known for their cellular heterogeneity, yet the molecular complexity within the cells of human plaques has not been fully assessed. Using single-cell transcriptomics and chromatin accessibility, we gained a better understanding of the pathophysiology underlying human atherosclerosis. We performed single-cell RNA and single-cell ATAC sequencing on human carotid atherosclerotic plaques to define the cells at play and determine their transcriptomic and epigenomic characteristics. We identified 14 distinct cell populations including endothelial cells, smooth muscle cells, mast cells, B cells, myeloid cells, and T cells and identified multiple cellular activation states and suggested cellular interconversions. Within the endothelial cell population, we defined subsets with angiogenic capacity plus clear signs of endothelial to mesenchymal transition. CD4+ and CD8+ T cells showed activation-based subclasses, each with a gradual decline from a cytotoxic to a more quiescent phenotype. Myeloid cells included 2 populations of proinflammatory macrophages showing IL (interleukin) 1B or TNF (tumor necrosis factor) expression as well as a foam cell-like population expressing TREM2 (triggering receptor expressed on myeloid cells 2) and displaying a fibrosis-promoting phenotype. ATACseq data identified specific transcription factors associated with the myeloid subpopulation and T cell cytokine profiles underlying mutual activation between both cell types. Finally, cardiovascular disease susceptibility genes identified using public genome-wide association studies data were particularly enriched in lesional macrophages, endothelial, and smooth muscle cells. This study provides a transcriptome-based cellular landscape of human atherosclerotic plaques and highlights cellular plasticity and intercellular communication at the site of disease. This detailed definition of cell communities at play in atherosclerosis will facilitate cell-based mapping of novel interventional targets with direct functional relevance for the treatment of human disease.
1633P Explorative model of imatinib resistant wild type GIST and potential immunotherapy strategies
Authors: E. Fiorino, G. Mesiano, I. Cerviere, E. Berrino, L. D’Ambrosio, A. Merlini, T. Venesio, Y. Pignochino, A. Pisacane, L. Gammaitoni, G. Grignani, M. Aglietta, D. Sangiolo
Journal: Annals of Oncology (2020)
1104P Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO
Authors: R. Gutzmer, T. Eigentler, P. Mohr, M. Weichenthal, P. Dücker, C. Gebhardt, D. Göppner, S. Haferkamp, K. Kähler, F. Meier, C. Pföhler, I. Satzger, T. Sickmann, A. Sindrilaru, P. Terheyden, S. Ugurel, J. Ulrich, J. Utikal, C. Weishaupt, D. Schadendorf
Journal: Annals of Oncology (2020)
Lower-Dose Zinc for Childhood Diarrhea — A Randomized, Multicenter Trial
Authors: Usha Dhingra, Rodrick Kisenge, Christopher R. Sudfeld, Pratibha Dhingra, Sarah Somji, Arup Dutta, Mohamed Bakari, Saikat Deb, Prabhabati Devi, Enju Liu, Aishwarya Chauhan, Jitendra Kumar, Om P. Semwal, Said Aboud, Rajiv Bahl, Per Ashorn, Jonathon Simon, Christopher P. Duggan, Sunil Sazawal, Karim Manji
Journal: New England Journal of Medicine (2020)

The World Health Organization recommends 20 mg of zinc per day for 10 to 14 days for children with acute diarrhea; in previous trials, this dosage decreased diarrhea but increased vomiting.
1110P Efficacy of salvage therapies after failure of anti-PD-1 monotherapy for advanced melanoma in an Asian population: A multi-institutional historical cohort study
Authors: Y. Teramoto, K. Namikawa, Y. Kiniwa, K. Yoshino, S. Yoshikawa, Y. Nakamura, T. Funakoshi, T. Takenouchi, T. Isei, T. Maekawa, T. Miyagawa, Y. Fujisawa, K. Yokota, T. Ito, H. Uhara, S. Matsushita, H. Doi, Y. Shibayama, S. Fukushima, N. Yamazaki
Journal: Annals of Oncology (2020)
320P Oligometastatic breast cancer incidence and clinical presentation at diagnosis: About 131 cases
Authors: J.L. Lacaze, C. Chira, G. Glemarec, R. Aziza, E. De Maio, F. Izar, E. Jouve, C. Massabeau, A. Pradines, G. Selmes, M. Ung, S. Zerdoud, F. Dalenc
Journal: Annals of Oncology (2020)
647P Clinical implications of intraductal carcinoma of the prostate sub-patterns in metastatic castration-resistant prostate cancer patients treated with abiraterone or docetaxel as the first-line therapy
Authors: W. Zhipeng, S. Zhu, J. Chen, J. Zhao, X. Zhang, G. Sun, N. Chen, H. Zeng
Journal: Annals of Oncology (2020)
1086P Cemiplimab for advanced cutaneous squamous cell carcinoma: Real life experience
Authors: C. Hober, L. Fredeau, A. Pham Ledard, M. Boubaya, F. Herms, F. Aubin, N. Benetton, M. Dinulescu, A. Jannic, L. Cesaire, N. Meyer, A.B. Duval Modeste, E. Archier, C. Lesage, N. Kramkimel, J.P. Arnault, F. Grange, S. Dalac, L. Mortier, E. Maubec
Journal: Annals of Oncology (2020)
Bacteria-derived long chain fatty acid exhibits anti-inflammatory properties in colitis
Authors: Julien Pujo, Camille Petitfils, Pauline Le Faouder, Venessa Eeckhaut, Gaelle Payros, Sarah Maurel, Teresa Perez-Berezo, Matthias Van Hul, Frederick Barreau, Catherine Blanpied, Stephane Chavanas, Filip Van Immerseel, Justine Bertrand-Michel, Eric Oswald, Claude Knauf, Gilles Dietrich, Patrice D Cani, Nicolas Cenac
Journal: Gut (2020)

Objective Data from clinical research suggest that certain probiotic bacterial strains have the potential to modulate colonic inflammation. Nonetheless, these data differ between studies due to the probiotic bacterial strains used and the poor knowledge of their mechanisms of action. Design By mass-spectrometry, we identified and quantified free long chain fatty acids (LCFAs) in probiotics and assessed the effect of one of them in mouse colitis. Results Among all the LCFAs quantified by mass spectrometry in Escherichia coli Nissle 1917 (EcN), a probiotic used for the treatment of multiple intestinal disorders, the concentration of 3-hydroxyoctadecaenoic acid (C18-3OH) was increased in EcN compared with other E. coli strains tested. Oral administration of C18-3OH decreased colitis induced by dextran sulfate sodium in mice. To determine whether other bacteria composing the microbiota are able to produce C18-3OH, we targeted the gut microbiota of mice with prebiotic fructooligosaccharides (FOS). The anti-inflammatory properties of FOS were associated with an increase in colonic C18-3OH concentration. Microbiota analyses revealed that the concentration of C18-3OH was correlated with an increase in the abundance in Allobaculum , Holdemanella and Parabacteroides . In culture, Holdemanella biformis produced high concentration of C18-3OH. Finally, using TR-FRET binding assay and gene expression analysis, we demonstrated that the C18-3OH is an agonist of peroxisome proliferator activated receptor gamma. Conclusion The production of C18-3OH by bacteria could be one of the mechanisms implicated in the anti-inflammatory properties of probiotics. The production of LCFA-3OH by bacteria could be implicated in the microbiota/host interactions.
Nanoparticles retard immune cells recruitment in vivo by inhibiting chemokine expression
Authors: Jianxiong Xu, Jinxuan Wang, Juhui Qiu, Hua Liu, Yi Wang, Yuliang Cui, Rose Humphry, Nan Wang, Colm DurKan, Yaokai Chen, Yanqiu Lu, Qinfeng Ma, Wei Wu, Yang Luo, Lehui Xiao, Guixue Wang
Journal: Biomaterials (2020)
LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER
Authors: F. Duffaud, J-Y. Blay, O. Mir, C.M. Chevreau, P. Boudou Rouquette, E. Kalbacher, N. Penel, C. Perrin, V. Laurence, E. Bompas, E. Saada-Bouzid, C. Delcambre, F. Bertucci, M. Cancel, C. Schiffler, L. Monard, C. Bouvier, V. Vidal, N. Gaspar, S. Chabaud
Journal: Annals of Oncology (2020)
404MO Clinical relevance of MIR27A rs895819 polymorphism and its interaction with DPYD variants for predicting grade 4-5 fluoropyrimidine (FP) toxicity (tox) in the FUSAFE individual patient data meta-analysis (IPD-MA)
Authors: M-C. Etienne-Grimaldi, N. Cozic, V. Boige, J-C. Boyer, D. Meulendijks, C. Palles, U. Zanger, C. Largiadèr, R.B. Diasio, B. Jennings, J. Taieb, M. Deenen, T. Marinaki, E. Gross, A. van Kuilenburg, F. Thomas-Jean, M-A. Loriot, J-P. Pignon, G. Le Teuff
Journal: Annals of Oncology (2020)
1920P Anlotinib in medullary thyroid carcinoma: A subanalysis based on ALTER01031 study for patients with high prognostic risk
Authors: M. Gao, Y. Chi, P. Tang, X. Zheng, Z. Xu, D. Li, X. Chen, M. Ge, Y. Zhang, Z. Guo, J. Wang, J. Chen, J. Zhang, Y. Cheng, Z. Li, H. Liu, J. Qin, J. Zhu, R. Cheng
Journal: Annals of Oncology (2020)
2004P Exome sequencing of germ-line DNA from young-onset and/or ALK-fusion-positive lung cancer patients
Authors: E. Imyanitov, A. Sokolenko, A. Iyevleva, V. Tiurin, T. Sokolova, A.O. Ivantsov, N. Mitiushkina, S. Orlov, E. Levchenko, I. Bizin
Journal: Annals of Oncology (2020)
1430P Patient-reported outcome (PRO) results from AGITG DOCTOR: A randomised phase II trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
Authors: R. Mercieca-Bebber, E.H. Barnes, K. Wilson, Z. Samoon, E.T. Walpole, T. Mai, S. Ackland, M. Burge, G. Dickie, D. Watson, J. Leung, T. Wang, R. Bohmer, D. Cameron, R. Simes, V. Gebski, M. Smithers, J. Thomas, J.R. Zalcberg, A. Barbour
Journal: Annals of Oncology (2020)
798TiP Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer
Authors: M.S. van der Heijden, S. Gupta, M.D. Galsky, C. Derleth, J. Steinberg, R. Kataria, T.B. Powles
Journal: Annals of Oncology (2020)

Platinum-containing chemotherapy is the standard of care for patients (pts) with metastatic urothelial carcinoma (mUC) in the first line (1L) setting. PD-1/PD-L1 inhibitors pembrolizumab (P) and atezolizumab are approved for 1L cisplatin (cis) ineligible pts (US and EU) and for those who are platinum-ineligible (P, US only) with high tumor PD-L1 expression. Enfortumab vedotin (EV) is an antibody drug conjugate (ADC) directed to Nectin-4, which is highly expressed in UC. Recently, EV received accelerated approval in the US for locally advanced (la)/mUC following treatment with PD 1/PD-L1 inhibitors and platinum-containing therapies in the neoadjuvant/adjuvant or la/mUC setting. In the EV-103 study (NCT03288545), EV + P showed a promising ORR of 73% in the cis-ineligible 1L setting with a manageable safety profile (Rosenberg ASCO-GU 2020). With only modest advances to date, the need for novel drug combinations to improve outcomes in the 1L setting for la/mUC remains. EV-302 (NCT04223856) began as a global 3-arm, open-label, randomized phase 3 study evaluating the efficacy and safety of EV + P (Arm A) and EV + P + cis/carboplatin (carbo) (Arm C) against standard gemcitabine (gem) + cis/carbo (Arm B) in pts with unresectable, previously untreated la/mUC. Recently, based on data from chemotherapy + PD-1/PD-L1 combinations, the study was modified to remove Arm C. The updated 2-arm design randomizes pts to EV + P or gem + cis/carbo. Randomization is 1:1 with the following stratification factors: cis eligibility, PD-L1 expression, and liver metastases. Pts must have measurable disease, an ECOG status of ≤2, and be able to receive EV, P and cis or carbo. EV (1.25 mg/kg) will be given on Days 1 and 8 of every 3-wk cycle. P (200 mg) will be given on Day 1. Gem (1000 mg/m2) will be given on Days 1 and 8 and cis (70 mg/m2) or carbo (AUC 4.5 or 5) on Day 1. The primary endpoints are PFS, assessed by blinded independent central review, and OS. Other endpoints include ORR, duration of response, disease control rate, AEs, and patient reported outcomes, as well as PK and biomarkers. The study opened in March 2020. NCT04223856. Medical writing assistance was funded by Seattle Genetics, Inc., and provided by Sarah Dreumont of Seattle Genetics, Inc. Seattle Genetics, Astellas, Merck. Seattle Genetics, Astellas, Merck.
Obesity‐Related Traits and the Development of Rheumatoid Arthritis: Evidence From Genetic Data
Authors: Bowen Tang, Huwenbo Shi, Lars Alfredsson, Lars Klareskog, Leonid Padyukov, Xia Jiang
Journal: Arthritis & Rheumatology (2020)

Objective To investigate the association between obesity‐related traits and risk of rheumatoid arthritis (RA). Methods We conducted genetic correlation analysis and a 2‐sample Mendelian randomization (MR) study, using genome‐wide genetic data based on &gt;850,000 individuals of European ancestry. Summary statistics were collected from the largest genome‐wide association study conducted to date for body mass index (BMI; n = 806,810), waist‐to‐hip ratio (WHR; n = 697,734), WHR adjusted for BMI (WHRadjBMI; n = 694,649), and RA (n case = 14,361, n control = 43,923). We conducted cross‐trait linkage disequilibrium score regression and ρ‐HESS analyses to quantify genetic correlation between pairs of traits (causal overlap). For each obesity‐related exposure, we utilized independent, genome‐wide significant single‐nucleotide polymorphisms ( P &lt; 5 × 10 −9 ) as instruments to perform MR analysis (causal relationship). We interrogated the causal relationship both in the general population and in a sex‐specific manner and calculated odds ratios (ORs) and 95% confidence intervals (95% CIs). Sensitivity analyses were performed to validate MR model assumptions. Results Despite a negligible overall genetic correlation between the 3 obesity‐related traits and RA, we found significant local genetic correlations at several regions on chromosome 6 (positions 28–29M, 30–35M, and 50–52M), highlighting a shared genetic basis. We further observed an increased risk of RA per SD increment (4.8 kg/m 2 ) in genetically predicted BMI (OR 1.22 [95% CI 1.09–1.37]). The effect was consistent across sensitivity analyses and comparable between sexes (OR 1.22 [95% CI 1.04–1.44] in male subjects and 1.19 [95% CI 1.04–1.36] in female subjects). However, we did not find evidence supporting a causal role of either WHR (OR 0.98 [95% CI 0.84–1.14]) or WHRadjBMI (OR 0.90 [95% CI 0.79–1.04]) in RA. Conclusion Genetically predicted BMI significantly increases RA risk. Future studies are needed to understand the biologic mechanisms underlying this link.
1558P Pancreatic cancer (PC) in patients (pts) younger than 50 years: Clinical outcomes and actionable genomic/genetic alterations
Authors: A. Garcia-Alvarez, H. Verdaguer, M. Guardiola, D.A. Acosta Eyzaguirre, E. Buxò, E. Sardo, N. Saoudi, D.H. Marmolejo Castaneda, J. Hernando, M. Diez Garcia, I. Baraibar Argota, F.J. Ros Montañá, A. Sierra, C. Molero, J.M. Miquel, A. Vivancos, R. Dienstmann, T. Macarulla Mercadé
Journal: Annals of Oncology (2020)
1843P Electro-acupuncture for quality of life in gastric cancer patients undergoing adjuvant chemotherapy
Authors: H-B. Zhang, Y-J. Zhu, J.J. Mao, J-J. Peng, X-S. Chang, X-Y. Wu, J. Wan, W. Wang, D-C. Diao, J. Xiao, Y. Li, D. Ma, M. Hu, J-C. Li, G-N. Wu, C-F. Ke, K-Y. Sun, Z-L. Huang, T-Y. Cao, Y-D. Chen
Journal: Annals of Oncology (2020)
1161MO Lanreotide autogel (LAN) and temozolomide (TMZ) combination therapy in progressive thoracic neuroendocrine tumours (TNETs): ATLANT study results
Authors: P. Ferolla, A. Berruti, F. Spada, M.P. Brizzi, T. Ibrahim, A. Colao, A. Faggiano, R. Marconcini, V. Vaccaro, D. Giuffrida, S. Ghizzoni, A. Houchard, N. Fazio
Journal: Annals of Oncology (2020)
Obesity in patients with COVID-19: a systematic review and meta-analysis
Authors: Yi Huang, Yao Lu, Yan-Mei Huang, Min Wang, Wei Ling, Yi Sui, Hai-Lu Zhao
Journal: Metabolism (2020)

BackgroundObesity is common in patients with coronavirus disease 2019 (COVID-19). The effects of obesity on clinical outcomes of COVID-19 warrant systematical investigation.ObjectiveThis study explores the effects of obesity with the risk of severe disease among patients with COVID-19.MethodsBody mass index (BMI) and degree of visceral adipose tissue (VAT) accumulation were used as indicators for obesity status. Publication databases including preprints were searched up to August 10, 2020. Clinical outcomes of severe COVID-19 included hospitalization, a requirement for treatment in an intensive care unit (ICU), invasive mechanical ventilation (IMV), and mortality. Risks for severe COVID-19 outcomes are presented as odds ratios (OR) and 95% confidence interval (95%CI) for cohort studies with BMI-defined obesity, and standardized mean difference (SMD) and 95%CI for controlled studies with VAT-defined excessive adiposity.ResultsA total of 45, 650 participants from 30 studies with BMI-defined obesity and 3 controlled studies with VAT-defined adiposity were included for assessing the risk of severe COVID-19. Univariate analyses showed significantly higher ORs of severe COVID-19 with higher BMI: 1.76 (95%: 1.21, 2.56, P = 0.003) for hospitalization, 1.67 (95%CI: 1.26, 2.21, P<0.001) for ICU admission, 2.19 (95%CI: 1.56, 3.07, P<0.001) for IMV requirement, and 1.37 (95%CI: 1.06, 1.75, P = 0.014) for death, giving an overall OR for severe COVID-19 of 1.67 (95%CI: 1.43, 1.96; P<0.001). Multivariate analyses revealed increased ORs of severe COVID-19 associated with higher BMI: 2.36 (95%CI: 1.37, 4.07, P = 0.002) for hospitalization, 2.32 (95%CI: 1.38, 3.90, P = 0.001) for requiring ICU admission, 2.63 (95%CI: 1.32, 5.25, P = 0.006) for IMV support, and 1.49 (95%CI: 1.20, 1.85, P<0.001) for mortality, giving an overall OR for severe COVID-19 of 2.09 (95%CI: 1.67, 2.62; P<0.001). Compared to non-severe COVID-19 patients, severe COVID-19 cases showed significantly higher VAT accumulation with a SMD of 0.49 for hospitalization (95% CI: 0.11, 0.87; P = 0.011), 0.57 (95% CI: 0.33, 0.81; P<0.001) for requiring ICU admission and 0.37 (95% CI: 0.03, 0.71; P = 0.035) for IMV support. The overall SMD for severe COVID-19 was 0.50 (95% CI: 0.33, 0.68; P<0.001).ConclusionsObesity increases risk for hospitalization, ICU admission, IMV requirement and death among patients with COVID-19. Further, excessive visceral adiposity appears to be associated with severe COVID-19 outcomes. These findings emphasize the need for effective actions by individuals, the public and governments to increase awareness of the risks resulting from obesity and how these are heightened in the current global pandemic.
773P Cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy: Safety and preliminary activity of the open-label, single-arm, phase II ARCADIA trial
Authors: L. Marandino, D. Raggi, P. Giannatempo, G. Calareso, A. Alessi, M. Colecchia, R. Madison, J.S. Ross, A. Necchi
Journal: Annals of Oncology (2020)
1091P Performance of Salamanca's refinement of the AJCC8 for T3 cutaneous squamous cell carcinoma (CSCC), versus the Brigham and Women's Hospital's alternative staging system and the Tübingen's alternative staging system for high-risk CSCC
Authors: L. Puebla-Tornero, L. Corchete-Sánchez, A. Conde-Ferreirós, N. García-Sancha, R. Corchado-Cobos, M.E. Cardeñoso-Álvarez, C. Román-Curto, J. Cañueto
Journal: Annals of Oncology (2020)
332P Treatment-emergent (TE) neutropenia and related hospitalizations and medication discontinuations in patients (pts) with metastatic breast cancer (MBC) treated with palbociclib (PAL) or ribociclib (RIB): A real-world analysis
Authors: L. Schwartzberg, H. Kanakamedala, A. Thuerigen, D. Chandiwana, C-L. Yu, S. Balu, S. Turner
Journal: Annals of Oncology (2020)
1604P Aggregated analysis of treatment and survival outcome of all metastatic renal cell carcinoma patients treated from 2014 to 2018 in the Veneto region, Italy
Authors: U. Basso, S. Tognazzo, A. Bortolami, M. Maruzzo, M. Ballestrin, D. Bimbatti, F. Pierantoni, V. Zagonel
Journal: Annals of Oncology (2020)
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform
Authors: Anna Schultze, Alex J Walker, Brian MacKenna, Caroline E Morton, Krishnan Bhaskaran, Jeremy P Brown, Christopher T Rentsch, Elizabeth Williamson, Henry Drysdale, Richard Croker, Seb Bacon, William Hulme, Chris Bates, Helen J Curtis, Amir Mehrkar, David Evans, Peter Inglesby, Jonathan Cockburn, Helen I McDonald, Laurie Tomlinson, Rohini Mathur, Kevin Wing, Angel Y S Wong, Harriet Forbes, John Parry, Frank Hester, Sam Harper, Stephen J W Evans, Jennifer Quint, Liam Smeeth, Ian J Douglas, Ben Goldacre
Journal: The Lancet Respiratory Medicine (2020)
The H<sub>4</sub>R is highly expressed on eosinophils from AD patients and IL‐4 upregulates expression and function via the JAK/STAT pathway
Authors: Katrin Schaper‐Gerhardt, Brigitta Köther, Luca Wolff, Aylin Kabatas, Manuela Gehring, Eirini Nikolouli, Susanne Mommert, Thomas Werfel, Ralf Gutzmer
Journal: Allergy (2020)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
1767P Hypercoagulable state, CD4+ T-lymphocytopenia, dysregulated cytotoxicity and monocyte upregulation in COVID-19 positive cancer patients presenting with severe pneumonia
Authors: J. Fuentes Antras, M. Viñuela, K. Guevara-Hoyer, E. de la Fuente, A. Manzano, G. Marquina Ospina, M. PAZ, A. Ocaña, M. Fernández-Arquero, S. Sánchez-Ramón, P. Pérez-Segura
Journal: Annals of Oncology (2020)
762P Molecular profiling of post-pembrolizumab muscle-invasive bladder cancer (MIBC) reveals unique features that may inspire new sequential therapies in pathologically-nonresponders
Authors: A. Necchi, J. de Jong, D. Raggi, A. Gallina, M. Bandini, P. Giannatempo, L. Marandino, M. Colecchia, A. Briganti, F. Montorsi, E. Davicioni, R. Seiler, P. Black, E. Gibb
Journal: Annals of Oncology (2020)
566P A multicenter, open-label, dose-escalation, first-in-man study of MetAP2 inhibitor M8891 in patients with advanced solid tumours
Authors: M.A. Carducci, D. Wang, C. Habermehl, M. Bödding, F. Rohdich, S. Stinchi, O. Karpenko, C. Gimmi, P. LoRusso
Journal: Annals of Oncology (2020)
1824P Incidence, risk factors and clinical outcome of venous and arterial thromboembolism in patients treated with immune-checkpoint inhibitors
Authors: F. Moik, W-S.E. Chan, S. Wiedemann, C. Höller, F. Tuchmann, M-B. Aretin, T. Füreder, S. Zöchbauer-Müller, M. Preusser, I. Pabinger, C. Ay
Journal: Annals of Oncology (2020)
431P A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: Updated results of JCOG1007 study (iPACS)
Authors: Y. Kanemitsu, K. Shitara, J. Mizusawa, T. Hamaguchi, D. Shida, K. Komori, S. Ikeda, H. Ojima, S. Hasegawa, A. Shiomi, J. Watanabe, Y. Takii, T. Yamaguchi, K. Katsumata, M. Ito, J. Okuda, R. Hyakudomi, Y. Shimada, H. Katayama, H. Fukuda
Journal: Annals of Oncology (2020)
Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19
Authors: Zhibo Liu, Xia Li, Guohui Fan, Fei Zhou, Yeming Wang, Lixue Huang, Jiapei Yu, Luning Yang, Lianhan Shang, Ke Xie, Jiuyang Xu, Zhisheng Huang, Xiaoying Gu, Hui Li, Yi Zhang, Yimin Wang, Zhenghui Huang, Bin Cao
Journal: Clinical Microbiology and Infection (2020)